The South & Central America influenza vaccines market is expected to grow from US$ 497.54 million in 2022 to US$ 736.35 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028.
Increase in Government Support to Promote Influenza Vaccination
The governing bodies of various states and countries are supporting the promotion of vaccination through multiple activities and programs. By 2022, enough vaccines have been secured to cover all risk groups eligible for a government-funded flu vaccine through the NIP.
Below are a few more instances supporting the government support for influenza vaccination: In Oct 2021, with flu season approaching, the Provincial Government was encouraging all Newfoundlanders and Labradorians to get a flu shot in the year 2021. Starting October 25, 2021, the Regional Health Authorities (RHAs) have begun hosting free flu vaccination clinics. People can also get the vaccine through their family doctor or local pharmacy. Thus, increasing government support to promote influenza vaccination is driving the South & Central America influenza vaccines market.
Market Overview
The South & Central America influenza vaccines market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market for influenza vaccines in the region is expected to experience growth opportunities during the forecast period. The influenza vaccines market in SAM is expected to grow owing to factors such as an increase in cases of influenza in the region, surge in various research activities in the region, rise in health awareness, and an increase in healthcare expenditure by the countries of the region.
South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)
South & Central America Influenza Vaccines Market Segmentation
The South & Central America influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.
Based on vaccine type, the South & Central America influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.
Based on virus type, the South & Central America influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.
Based on technology, the South & Central America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.
Based on route of administration, the South & Central America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.
Based on target group, the South & Central America influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.
Based on country, the South & Central America influenza vaccines market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market in 2022.
AstraZeneca; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the South & Central America influenza vaccines market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 497.54 Million |
| Market Size by 2028 | US$ 736.35 Million |
| CAGR (2022 - 2028) | 6.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Vaccine Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South & Central America Influenza Vaccines Market is valued at US$ 497.54 Million in 2022, it is projected to reach US$ 736.35 Million by 2028.
As per our report South & Central America Influenza Vaccines Market, the market size is valued at US$ 497.54 Million in 2022, projecting it to reach US$ 736.35 Million by 2028. This translates to a CAGR of approximately 6.8% during the forecast period.
The South & Central America Influenza Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Influenza Vaccines Market report:
The South & Central America Influenza Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Influenza Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Influenza Vaccines Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Influenza Vaccines Market
